{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:59Z","timestamp":1790255219056,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Government of Catalonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201291","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:35:17Z","timestamp":1783726517000},"page":"201291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic adenovirus incorporating TetO sites in the E1A promoter for controlled replication in TetR-expressing mesenchymal stem cells"],"prefix":"10.1016","volume":"34","author":[{"given":"Ramon","family":"Alemany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Torres-Manjon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Traveset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3105","authenticated-orcid":false,"given":"Rafael","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201291_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-023-04817-w","article-title":"Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201291_bib2","first-page":"4192","article-title":"Advances in the clinical development of oncolytic viruses","volume":"14","author":"Li","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.omton.2026.201291_bib3","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201291_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-014-1537-7","article-title":"Cancer gene therapy using mesenchymal stem cells","volume":"99","author":"Uchibori","year":"2014","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omton.2026.201291_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142296","article-title":"Cell Carriers for Oncolytic Virus Delivery: Prospects for Systemic Administration","volume":"17","author":"Sarkisova","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201291_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001684","article-title":"Mesenchymal stem cells and oncolytic viruses: joining forces against cancer","volume":"9","author":"Moreno","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201291_bib7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201291_bib8","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/cancers12051104","article-title":"Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient","volume":"12","author":"Franco-Luz\u00f3n","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201291_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jgm.384","article-title":"A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver","volume":"5","author":"Tietge","year":"2003","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omton.2026.201291_bib10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/JVI.72.3.2289-2296.1998","article-title":"Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Regulatable Expression Cassette","volume":"72","author":"Massie","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201291_bib11","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/sj.gt.3302051","article-title":"A novel tetracycline-controlled transactivator\u2013transrepressor system enables external control of oncolytic adenovirus replication","volume":"10","author":"Fechner","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2026.201291_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/scrt53","article-title":"Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia","volume":"2","author":"McGinley","year":"2011","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.omton.2026.201291_bib13","article-title":"Characterization of Constitutive Promoters for piggyBac Transposon-Mediated Stable Transgene Expression in Mesenchymal Stem Cells (MSCs)","volume":"9","author":"Wen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201291_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients","volume":"30","author":"Garc\u00eda","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201291_bib15","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.3390\/ijms21207505","article-title":"Clinical Application of Oncolytic Viruses: A Systematic Review","volume":"21","author":"Cook","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.omton.2026.201291_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.omton.2026.201291_bib17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2026.201291_bib18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/gt.2008.40","article-title":"Taming the Trojan horse: optimizing dynamic carrier cell\/oncolytic virus systems for cancer biotherapy","volume":"15","author":"Power","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2026.201291_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172991","article-title":"Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses","volume":"874","author":"Hadry\u015b","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omton.2026.201291_bib20","article-title":"Optimized protocol for culturing menstrual blood-derived MSCs for combination with oncolytic adenoviruses in cancer treatment","volume":"32","author":"Costa-Garcia","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201291_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/v11020141","article-title":"Metabolic Reprogramming of the Host Cell by Human Adenovirus Infection","volume":"11","author":"Prusinkiewicz","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2026.201291_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cmet.2014.03.009","article-title":"Adenovirus E4ORF1-Induced MYC Activation Promotes Host Cell Anabolic Glucose Metabolism and Virus Replication","volume":"19","author":"Thai","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.omton.2026.201291_bib23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/ijms22010464","article-title":"Metabolome-Driven Regulation of Adenovirus-Induced Cell Death","volume":"22","author":"Laevskaya","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.omton.2026.201291_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1566523216666160524144041","article-title":"Tet-On Systems For Doxycycline-inducible Gene Expression","volume":"16","author":"Das","year":"2016","journal-title":"CGT"},{"key":"10.1016\/j.omton.2026.201291_bib25","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/sj.gt.3301813","article-title":"Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2s-M2 tetracycline transactivator and repressor system","volume":"9","author":"Salucci","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2026.201291_bib26","doi-asserted-by":"crossref","first-page":"13670","DOI":"10.1073\/pnas.95.23.13670","article-title":"Graded transcriptional response to different concentrations of a single transactivator","volume":"95","author":"Kringstein","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201291_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/clinids\/22.3.441","article-title":"Treatment of Human Brucellosis with Netilmicin and Doxycycline","volume":"22","author":"Solera","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.omton.2026.201291_bib28","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3389\/fimmu.2020.02044","article-title":"Externally-Controlled Systems for Immunotherapy: From Bench to Bedside","volume":"11","author":"Trist\u00e1n-Manzano","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201291_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2022.09.004","article-title":"Enhanced tumor targeting and timely viral release of mesenchymal stem cells\/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment","volume":"27","author":"Choi","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201291_bib30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jbiotec.2006.09.011","article-title":"A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication","volume":"127","author":"Fechner","year":"2007","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.omton.2026.201291_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1128\/JVI.02668-13","article-title":"Switching a Replication-Defective Adenoviral Vector into a Replication-Competent, Oncolytic Adenovirus","volume":"88","author":"Nakashima","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201291_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/1535-7163.MCT-18-0431","article-title":"Enhanced Antitumor Efficacy of Oncolytic Adenovirus\u2013loaded Menstrual Blood\u2013derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells","volume":"18","author":"Moreno","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2026.201291_bib33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201291_bib34","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2010.173","article-title":"Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses","volume":"18","author":"Rojas","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201291_bib35","first-page":"1266","article-title":"Treatment of ovarian cancer with a tropism modified oncolytic adenovirus","volume":"62","author":"Bauerschmitz","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201291_bib36","doi-asserted-by":"crossref","first-page":"45415","DOI":"10.18632\/oncotarget.17557","article-title":"Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model","volume":"8","author":"Rinc\u00f3n","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201291_bib37","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/0008-5472.CAN-03-3061","article-title":"Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors","volume":"64","author":"Zabala","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201291_bib38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/sj.cgt.7700940","article-title":"Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-\u039424RGD","volume":"13","author":"Majem","year":"2006","journal-title":"Cancer Gene Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:42:23Z","timestamp":1790253743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001670"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201291","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus incorporating TetO sites in the E1A promoter for controlled replication in TetR-expressing mesenchymal stem cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201291"}}